ATE361676T2 - Verwendung von docosapentsaeure enthaltendem material - Google Patents

Verwendung von docosapentsaeure enthaltendem material Download PDF

Info

Publication number
ATE361676T2
ATE361676T2 AT00906735T AT00906735T ATE361676T2 AT E361676 T2 ATE361676 T2 AT E361676T2 AT 00906735 T AT00906735 T AT 00906735T AT 00906735 T AT00906735 T AT 00906735T AT E361676 T2 ATE361676 T2 AT E361676T2
Authority
AT
Austria
Prior art keywords
relieving
maintaining
vivo
fatty acid
deficient conditions
Prior art date
Application number
AT00906735T
Other languages
English (en)
Inventor
Osamu Igarashi
Kengo Akimoto
Toshiaki Yaguchi
Yoshinobu Kiso
Original Assignee
Suntory Ltd
Nagase & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13065097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361676(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Suntory Ltd, Nagase & Co Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE361676T2 publication Critical patent/ATE361676T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00906735T 1999-03-04 2000-03-06 Verwendung von docosapentsaeure enthaltendem material ATE361676T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5776999 1999-03-04

Publications (1)

Publication Number Publication Date
ATE361676T2 true ATE361676T2 (de) 2007-06-15

Family

ID=13065097

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906735T ATE361676T2 (de) 1999-03-04 2000-03-06 Verwendung von docosapentsaeure enthaltendem material

Country Status (13)

Country Link
US (1) US6596766B1 (de)
EP (1) EP1166652B2 (de)
JP (1) JP4518674B2 (de)
KR (2) KR100423013B1 (de)
AT (1) ATE361676T2 (de)
AU (1) AU766660C (de)
CA (1) CA2362515C (de)
CY (1) CY1106783T1 (de)
DE (1) DE60034775T3 (de)
DK (1) DK1166652T4 (de)
ES (1) ES2286999T5 (de)
PT (1) PT1166652E (de)
WO (1) WO2000051444A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094089A1 (en) * 1988-09-07 2006-05-04 Martek Biosciences Corporation Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
ATE374531T1 (de) 2000-01-28 2007-10-15 Martek Biosciences Corp Verstaerkte produktion von lipiden enthaltend mehrfachungesaettigte fettsaeuren durch hochdichte kulturen von eukariotischen mikroben in gaervorrichtungen
ES2343106T3 (es) 2000-09-28 2010-07-23 BIORIGINAL FOOD & SCIENCE CORP. Fad4, fad5, fad5-2 y fad6, miembros de la familia de desaturasas de acidos grasos y usos de los mismos.
US7223434B2 (en) * 2001-11-21 2007-05-29 Gerber Products Company Blended baby foods
AU2002234611A1 (en) * 2002-01-10 2003-07-24 Puleva Biotech, S.A. Oil blends
ES2221576B1 (es) * 2003-06-11 2006-03-16 Puleva Biotech, S.A. Mezclas de aceites.
US8921422B2 (en) * 2003-10-01 2014-12-30 The Iams Company Methods and kits for enhancing ability to learn in a puppy or kitten
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
JP2008520739A (ja) * 2004-11-19 2008-06-19 マーテック・バイオサイエンシーズ・コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP4893914B2 (ja) * 2004-12-02 2012-03-07 公立大学法人島根県立大学 経管栄養組成物
DE102005003624A1 (de) * 2005-01-26 2006-07-27 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Herstellung und Anwendung eines antioxidativ wirksamen Extraktes aus Crypthecodinium sp.
EP3238543B1 (de) 2005-06-07 2019-03-20 DSM Nutritional Products AG Eukaryotische mikroorganismen zur herstellung von lipiden und antioxidantien
KR20180026556A (ko) * 2005-07-08 2018-03-12 디에스엠 아이피 어셋츠 비.브이. 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
WO2007090162A2 (en) * 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
CA2659603C (en) * 2006-08-01 2017-03-07 Ocean Nutrition Canada Limited Oil producing microbes and methods of modification thereof
EP2420146A1 (de) * 2006-08-29 2012-02-22 Martek Biosciences Corporation Verwendung von DPA(n-6)-Ölen bei Babynahrung
EP2120920A4 (de) * 2007-02-20 2011-06-15 Martek Biosciences Corp Oxylipine aus langkettigen mehrfach ungesättigten fettsäuren sowie verfahren zu ihrer herstellung und verwendung
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
US20090202672A1 (en) * 2008-02-11 2009-08-13 Monsanto Company Aquaculture feed, products, and methods comprising beneficial fatty acids
EP2145942A1 (de) * 2008-07-15 2010-01-20 Lonza Ltd. Verfahren zur Isolierung von Ölen aus Zellen und Biomasse
EP3187182B1 (de) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
US8207363B2 (en) * 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
PL2424356T3 (pl) 2009-04-29 2018-03-30 Amarin Pharmaceuticals Ireland Limited Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
JP5920890B2 (ja) 2010-01-19 2016-05-18 ディーエスエム アイピー アセッツ ビー．ブイ． エイコサペンタエン酸生成微生物、脂肪酸組成物、ならびにそれらを作る方法およびそれらの使用
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9222112B2 (en) 2011-07-21 2015-12-29 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
MX2020008890A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
US8747916B1 (en) 2012-10-30 2014-06-10 Donald M. Smith Selecting, producing, and feeding whole algae as a feed supplement for cattle and bison to produce meat high in omega 3's for human health
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
WO2014141098A1 (en) 2013-03-13 2014-09-18 Dsm Nutritional Products Ag Engineering microorganisms
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2947246C (en) * 2014-05-08 2024-02-27 Donald M. Smith Selecting, producing, and feeding whole algae as a feed supplement for cattle and bison to produce meat high in omega 3's for human health
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AR104042A1 (es) 2015-03-26 2017-06-21 Mara Renewables Corp Producción de alta densidad de biomasa y aceite utilizando glicerol en bruto
MX2018000502A (es) 2015-07-13 2018-09-07 Mara Renewables Corp Mejora del metabolismo de microalga de xilosa.
US20180192669A1 (en) * 2015-10-01 2018-07-12 Dsm Ip Assets B.V. Supplement material for use in pet food
CN105746908B (zh) * 2016-02-23 2018-08-28 广州英赛特生物技术有限公司 肉豆蔻酸衍生物在制备动物生长促进剂中的应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
SG10201900614PA (en) * 2019-01-23 2020-08-28 Agency For Science Technology And Research Astarstar Maternal DPA for benefit of mother and/or child’s mental health
TWI815067B (zh) * 2019-12-26 2023-09-11 日商瑪魯哈日魯股份有限公司 包含結合有多元不飽合脂肪酸之磷脂質之魚卵脂質組成物
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH075484B2 (ja) 1985-03-06 1995-01-25 帝人株式会社 血液脳関門通過性医薬品組成物
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
JP3627043B2 (ja) 1996-04-24 2005-03-09 明治乳業株式会社 ｎ−６系列／ｎ−３系列脂肪酸バランス 改善ヌクレオチド含有乳児用食品
DE69737063T2 (de) * 1996-07-23 2007-07-19 Nagase Chemtex Corp. Verfahren zur herstellung von decosahexaensäure und decosapentsäure
JP3573595B2 (ja) * 1997-05-30 2004-10-06 株式会社ベルリッチ 高度不飽和脂肪酸及び／又はそのエステルを含有する組成物

Also Published As

Publication number Publication date
DE60034775D1 (de) 2007-06-21
AU766660B2 (en) 2003-10-23
DE60034775T3 (de) 2016-11-24
DE60034775T2 (de) 2008-01-17
CY1106783T1 (el) 2012-05-23
ES2286999T3 (es) 2007-12-16
KR100423013B1 (ko) 2004-03-12
CA2362515A1 (en) 2000-09-08
CA2362515C (en) 2008-07-15
EP1166652B1 (de) 2007-05-09
KR20010108311A (ko) 2001-12-07
DK1166652T4 (en) 2016-10-24
JP4518674B2 (ja) 2010-08-04
WO2000051444A1 (fr) 2000-09-08
AU2830600A (en) 2000-09-21
KR20040014597A (ko) 2004-02-14
EP1166652A4 (de) 2002-05-29
DK1166652T3 (da) 2007-09-10
US6596766B1 (en) 2003-07-22
PT1166652E (pt) 2007-08-20
EP1166652B2 (de) 2016-07-13
KR100504324B1 (ko) 2005-07-28
ES2286999T5 (es) 2016-11-17
AU766660C (en) 2004-05-06
EP1166652A1 (de) 2002-01-02

Similar Documents

Publication Publication Date Title
ATE361676T2 (de) Verwendung von docosapentsaeure enthaltendem material
DE60131804D1 (de) Verwendung von alpha-Ketoenaminderivaten als kühlende Mittel
DE69626513T2 (de) Imidazolverbindungen
ATE204460T1 (de) Gelstiftzusammensetzung enthaltend gebildner angereichert in optisch aktiver form
YU88601A (sh) Antifungalna oralna kompozicija koja sadrži itrakonazol i postupak za dobijanje iste
NZ294464A (en) Stable, aqueous formulation having high biological alpha-type interferon activity buffered from 4.5 to 7.1 and comprising chelating agent and a polyoxyethylene sorbitan monooleate, formulation free from human blood-derived products
BG105709A (en) Piperidines as ccr5 modulatiors
DE69210361D1 (de) Orale Formulierung zum verbesserten Bleichen von Zähnen
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
SE8702831L (sv) Microbicid komposition
FR2792191B1 (fr) Composition cosmetique comprenant l'association d'un ester particulier et d'un compose silicone
MXPA02004617A (es) Lipoxin a4 y sus analagos para el tratamiento de ojo reseco.
ES2193919T3 (es) Inhibidores de la enzima convertidora de endotelina.
NZ239022A (en) Piperidyl ethers and thioethers; preparatory processes and pharmaceutical compositions
AR005860A1 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización.
ITMI910456A1 (it) Composizione farmaceutica per il trattamento della cataratta
DE59812044D1 (de) Verwendung von Ceramiden zur Haarpflege
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
ES2135745T3 (es) Mezclas fungicidas.
ATE258042T1 (de) Zweikomponenten-mundspülmittel
ATE281824T1 (de) Mittel zum blondieren von menschlichen haaren enthaltend poly-(n-acylalkylenimin) modifizierte organopolysikoxane
JPS5585518A (en) Bile secretionnactive organism and therapeutic composition containing it as active ingredient
IT1307866B1 (it) Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento
TR199802070A2 (xx) B�cek zehiri kompozisyonu

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1166652

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner